» Articles » PMID: 28560421

A Novel Damage Mechanism: Contribution of the Interaction Between Necroptosis and ROS to High Glucose-induced Injury and Inflammation in H9c2 Cardiac Cells

Overview
Journal Int J Mol Med
Specialty Genetics
Date 2017 Jun 1
PMID 28560421
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, a novel mechanism known as 'programmed necrosis' or necroptosis has been shown to be another important mechanism of cell death in the heart. In this study, we investigated the role of necroptosis in high glucose (HG)-induced injury and inflammation, as well as the underlying mechanisms. In particular, we focused on the interaction between necroptosis and reactive oxygen species (ROS) in H9c2 cardiac cells. Our results demonstrated that the exposure of H9c2 cardiac cells to 35 mM glucose (HG) markedly enhanced the expression level of receptor-interacting protein 3 (RIP3), a kinase which promotes necroptosis. Importantly, co-treatment of the cells with 100 µM necrostatin-1 (a specific inhibitor of necroptosis) and HG for 24 h attenuated not only the increased expression level of RIP3, but also the HG-induced injury and inflammation, as evidenced by an increase in cell viability, a decrease in ROS generation, the attenuation of the dissipation of mitochondrial membrane potential and a decrese in the secretion levels of inflammatory cytokines, i.e., interleukin (IL)-1β and tumor necrosis factor (TNF)-α. Furthermore, treatment of the cells with 1 mM N-acetyl‑L‑cysteine (a scavenger of ROS) for 60 min prior to exposure to HG significantly reduced the HG-induced increase in the RIP3 expression level, as well as the injury and inflammatory response described above. Taken together, the findings of this study clearly demonstrate a novel damage mechanism involving the positive interaction between necroptosis and ROS attributing to HG-induced injury and inflammation in H9c2 cardiac cells.

Citing Articles

Non-apoptotic programmed cell deaths in diabetic pulmonary dysfunction: the new side of advanced glycation end products.

Dai Y, Zhou S, Qiao L, Peng Z, Zhao J, Xu D Front Endocrinol (Lausanne). 2023; 14:1126661.

PMID: 37964954 PMC: 10641270. DOI: 10.3389/fendo.2023.1126661.


Role of RIPK3‑CaMKII‑mPTP signaling pathway‑mediated necroptosis in cardiovascular diseases (Review).

Chen S, Guan S, Yan Z, Ouyang F, Li S, Liu L Int J Mol Med. 2023; 52(4).

PMID: 37654208 PMC: 10495754. DOI: 10.3892/ijmm.2023.5301.


RIPK1 is aberrantly expressed in multiple B-cell cancers and implicated in the underlying pathogenesis.

Wu B, Li J, Wang H, Liu J, Li J, Sun F Discov Oncol. 2023; 14(1):131.

PMID: 37462822 PMC: 10353973. DOI: 10.1007/s12672-023-00725-z.


Dihydropyrazole Derivatives Act as Potent α-Amylase Inhibitors and Free Radical Scavengers: Synthesis, Bioactivity Evaluation, Structure-Activity Relationship, ADMET, and Molecular Docking Studies.

Ali A, Shah M, Fu C, Hussain Z, Nasimullah Qureshi M, Farman S ACS Omega. 2023; 8(23):20412-20422.

PMID: 37332823 PMC: 10268634. DOI: 10.1021/acsomega.3c00529.


The Potential Role of Regulated Cell Death in Dry Eye Diseases and Ocular Surface Dysfunction.

Scarpellini C, Ramos Llorca A, Lanthier C, Klejborowska G, Augustyns K Int J Mol Sci. 2023; 24(1).

PMID: 36614174 PMC: 9820812. DOI: 10.3390/ijms24010731.